The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC-Reference-Cited by-同舟云学术

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

Published:2017-02 Issue:2 Volume:12 Page:194-207
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Manegold Christian,Dingemans Anne-Marie C.,Gray Jhanelle E.,Nakagawa Kazuhiko,Nicolson Marianne,Peters Solange,Reck Martin,Wu Yi-Long,Brustugun Odd Terje,Crinò Lucio,Felip Enriqueta,Fennell Dean,Garrido Pilar,Huber Rudolf M.,Marabelle Aurélien,Moniuszko Marcin,Mornex Françoise,Novello Silvia,Papotti Mauro,Pérol Maurice,Smit Egbert F.,Syrigos Kostas,van Meerbeeck Jan P.,van Zandwijk Nico,Chih-Hsin Yang James,Zhou Caicun,Vokes Everett

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference63 articles.

1. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease;Besse;Ann Oncol,2014

2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. Version 4. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 21, 2016.

3. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Reck;Ann Oncol,2014

4. Second-line treatment of advanced non-small cell lung cancer;Gridelli;J Thorac Oncol,2008

5. The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?;Gridelli;Clin Lung Cancer,2010

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study;Neoplasia;2024-11

2. Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival;Anti-Cancer Agents in Medicinal Chemistry;2024-07

3. A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review;Pathology - Research and Practice;2024-07

4. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study;BMC Cancer;2024-06-11

5. Comparison of the efficacy and safety of different dose anlotinib in combination with immune checkpoint inhibitors for patients with advanced non-small cell lung cancer;2024-06-07